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Summary Multidrug resistance phenotypes in human tumours are associated with the overexpression of the
170 kDa P-glycoprotein encoded by the multidrug resistance 1 (MDRI) gene, and also with that of the
non-P-glycoprotein-mediated multidrug resistance gene, MRP, which encodes a 190 kDa membrane ATP-
binding protein. We have previously reported that overexpression of MRP appears to be responsible for
spontaneous multidrug resistance in some human glioma cell lines (Abe et al., Int. J. Cancer, 58, 860-864,
1994). In this study, we investigated whether chemosensitising agents of P-glycoprotein-mediated multidrug
resistance such as verapamil, a biscoclaurine alkaloid (cepharanthine), and a dihydropyridine analogue
(NIK250) could also reverse multidrug resistance in human glioma cells. The glioma cell lines were the two
MRP-expressing cell lines, T98G and IN500, an MDRJ-expressing cell line, CCF-STTGI, and the MRP/
MDRJ-non-expressing cell line, IN157. Verapamil and NIK250 almost completely reversed drug resistance to
vincristine, etoposide and doxorubicin in T98G cells, while they also reversed drug resistance to vincristine and
etoposide, but only partially to doxorubicin in IN500 cells. Cepharanthine as well as verapamil and NIK250
reversed vincristine resistance in CCF-STTGI cells, but cepharanthine only partially reversed drug resistance
in T98G and IN500 cells. The cellular accumulation of [3H]etoposide increased about 2- and 3-fold compared
with control in T98G cells in the presence of verapamil and NIK250 respectively. Furthermore, the release of
doxorubicin from the nuclei of T98G cells was blocked by N1K250. However, NIK250 and verapamil caused
no apparent increase in vincristine accumulation in T98G cells. NIK250 or verapamil might exert inhibitory
effects upon MRP function, resulting in a reversal of MRP-mediated spontaneous multidrug resistance in
cultured human glioma cells.
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The appearance of multidrug-resistant tumours is a serious
problem in cancer chemotherapy. The overexpression of a
membrane P-glycoprotein (P-gp) with a molecular weight of
170kDa, encoded by the MDRI gene, is often associated
with the acquisition of multidrug resistance (MDR) pheno-
types (Bradley et al., 1988). Reduced drug retention in P-gp-
overexpressing cells is due to the enhanced active efflux of
anti-cancer agents. MDRJ is often overexpressed in various
tumours in cancer patients (Goldstein et al., 1989). However,
the expression of the MDRJ-encoded P-gp is not always
coupled with the acquisition of MDR in various human
tumour cell lines. Cole et al. (1992) have recently isolated a
gene named MRP from a doxorubicin-resistant small-cell
lung carcinoma cell line with the MDR phenotype (Mirski et
al., 1987). This MRP gene is amplified in some multidrug
resistant cell lines (Krishnamachary and Center, 1993; Bar-
rand et al., 1994). Zaman et al. (1993) have further demon-
strated that MRP is 25-fold overexpressed in a non-P-gp
small-cell lung cancer cell line, but not in other non-P-gp
MDR cell lines derived from non-small-cell lung cancers. The
human breast carcinoma cell line MCF7, which is selected
for etoposide resistance, and which overexpresses the MRP
gene, is resistant to etoposide and doxorubicin, and shows
low-level cross-resistance to vincristine and mitoxantrone
(Schneider et al., 1994). Furthermore, Grant et al. (1994)
have demonstrated that HeLa cells transfected with an MRP
expression vector display an increase in resistance to dox-
orubicin, vincristine and etoposide, but not to cisplatin. MRP
is a member of the ATP-binding cassette (ABC) superfamily
transport system proposed by Hyde et al. (1990), but MRP
has minor sequence homology with the P-gp encoded by the
human MDR] gene (Cole et al., 1992). We have previously
reported that two of seven glioma cell lines, IN500 and
T98G, which have elevated MRP mRNA levels are resistant
to multiple anti-cancer agents such as etoposide, vincristine
and doxorubicin, and that there is decreased intracellular
accumulation of etoposide (Abe et al., 1994a).
To reverse multidrug resistance, many agents have been
investigated. Calcium channel blockers such as verapamil,
nicardipine and others reportedly overcome drug resistance in
vitro and in vivo (Tsuruo et al., 1981). The clinical use of
calcium channel blockers, however, might pose a therapeutic
problem because they are powerful vasodilators. We have
reported that some dihydropyridine analogues can overcome
multidrug resistance in cancer cell lines as well as in
leukaemia-bearing mice (Kiue et al., 1990a,b; Kiue et al.,
1991; Watanabe et al., 1991). We also reported that cephar-
anthine, a bisbenzylisoquinoline biscoclaurine alkaloid,
completely overcomes the resistance of multidrug-resistant
sublines derived from human KB carcinoma cells (Shiraishi
et al., 1987). NIK250 and other dihydropyridine analogues as
well as cepharanthine and verapamil specifically inhibit the
photoaffinity labelling of radioactive azidopine to P-gp of
membrane vesicles of MDRJ-overexpressing cancer cells, sug-
gesting that they have high affinity for P-gp (Cornwell et al.,
1987; Akiyama et al., 1988; Kiue et al., 1990b; Watanabe et
al., 1991). On the other hand, it has been demonstrated that
cyclosporin A and its derivatives, as well as verapamil,
modify non-P-gp-mediated multidrug resistance, but their
chemosensitisation is not effective (Slovak et al., 1988; Cole
et al., 1989; Meijer et al., 1991; Barrand et al., 1993). In this
study, we investigated whether NIK250 as well as verapamil
and cepharanthine could potentiate etoposide, doxorubicin
and vincristine in multidrug-resistant human glioma cell lines
that overexpress the MRP gene in vitro.
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Materials and methods
Tumour cell lines
The glioma cell lines IN157, IN500, T98G and CCF-STTGI,
derived from patients with glioma, were studied (Abe et al.,
1993, 1994a,b). These human glioma cell lines were cultured
in Dulbecco's modified Eagle medium (DMEM) supplement-
ed with 10% fetal bovine serum (FBS), 100 units ml-l
penicillin and 60 mg ml1' kanamycin as described previously
(Abe et al., 1993, 1994a).
Northern blot analysis
A human MRP cDNA probe (1 kb EcoRI fragment) was
provided by SPC Cole (Queens University, Ontario, Canada)
(Cole et al., 1992). Human MDR1 cDNA was from MM
Gottesman (NCI, NIH, Bethesda, MD, USA), human topo-
isomerase I cDNA probe from 0 Koiwaki and T Andoh
(Aichi Cancer Center, Nagoya, Japan) and human topo-
isomerase 1Ia probe (pBS-hTOP2) from JC Wang (Harvard
University, USA). Northern blotting was performed as des-
cribed previously (Abe et al., 1993; Kohno et al., 1994).
Glioma cells were incubated in DMEM containing 10%
FBS, and harvested cells were suspended in 4 M guanidinum
thiocyanate, 25 mM sodium citrate (pH 7.0), 0.5% sarcosyl
and 0.1 M ,-mercaptoethanol. Thereafter, 2 M sodium acetate
(pH 4.0), water-saturated phenol and chloroform were suc-
cessively added. After vigorous mixing, the samples were left
on ice for 20 min, then centrifuged at 10000 g for 20 min.
The aqueous phase was separated into portions, mixed with
isopropanol and stored at -20°C for 20 min. The samples
were then centrifuged at 10 000 g for 20 min to obtain the
RNA pellet, which was washed with 75% ethanol and dis-
solved in sterile, RNAse-free water. The RNA was fraction-
ated through a 1% agarose gel containing 2.2 M formalde-
hyde and transferred onto a Nytran filter (Schleicher and
Schuell). The mRNA levels were quantified by densitometry
using a Fujix BAS 2000 bioimaging analyser (Fuji Photo
Film, Tokyo, Japan).
Drug and chemicals
Doxorubicin was a gift from Kyowa Pharmaceuticals,
Tokyo, Japan; vincristine was from Shionogi Pharma-
ceuticals, Tokyo, Japan; etoposide was from Nihon Kayaku,
Tokyo, Japan; NIK250 (Figure 1) (Kiue et al., 1990a, 1991;
Watanabe et al., 1991) was from Nikken Chemicals, Saitama,
Japan; Cepharanthine (Figure 1) (Shiraishi et al., 1987) was
from Kaken Shoyaku, Tokyo, Japan; Verapamil was from
Eizai, Tokyo, Japan, [3H]etoposide (388 Ci mmolh') was
obtained from Moravek Biochemicals (Brea, CA, USA) and
[3H]vincristine (4.8 Ci mmolh ) was obtained from New Eng-
land Nuclear.
Cell survival by colonyformation
Cell survival was determined by plating about 103 cells in
35 mm dishes (Abe et al., 1994a) then adding various drugs
24 h later. After incubation for 7 days at 37°C, the number of
colonies was counted after Giemsa staining. All drugs were
freshly prepared in physiological saline or dimethylsulphox-
ide. All control experiments included the same amount of
saline or dimethylsulphoxide. The 90% lethal dose (LD50) for
each glioma cell line was determined from dose-response
curves. Relative resistance were determined from three
separate experiments.
Drug accumulation
Cells (2 x 105 per well; 24 well plate) were plated and
incubated for 48 h at 37°C. After reaching subconfluence, the
plates were incubated on ice in water at 4°C for 15 min and
washed twice with ice-cold phosphate-buffered saline (PBS).
The medium was then replaced with 200 gil of buffer (serum-
free DMEM and 20 mM HEPES, pH 7.5) containing [3H]-
etoposide and [3H]vincristine, and the cells were incubated at
37°C with or without verapamil, cepharanthine or NIK250.
The cells were then washed three times with ice-cold PBS,
then 400 jil of 0.25 M sodium hydroxide was added, and the
cells were incubated at 37°C for over 30 min. The cellular
pellets were mixed thoroughly with 4ml of Scintisol EX-H
(Wako, Osaka, Japan) and the radioactivity was counted.
Fluorescent microscopy
Glioma cells in exponential growth were centrifuged, sus-
pended in DMEM-10% FBS at 1 x 105ml-', seeded onto
glass slides and incubated at 37°C for 24 h. The cells were
subsequently incubated in presence of doxorubicin 1 jig ml-'
with or without verapamil, cepharanthine or NIK250 for
40 min at 37°C, then incubated in its absence with or without
verapamil, cepharanthine or NIK250 for 120 min at 37°C,
followed by washing with ice-cold PBS twice, and mounted
in 50% glycerol in PBS. The fluorescence of doxorubicin in
the cells was examined by Leica fluorescence microscopy with
a Bio-Rad laser scanning confocal imaging system (MRC-
1000) as described previously (Abe et al., 1994a; Hasegawa et
al., 1995).
Results
Drug resistance to several anti-cancer agents infour human
glioma cell lines
We have previously reported overexpression of the MRP
gene in the two human glioma cell lines, T98G and IN500,
but not in IN157. The first two, but not the last, showed
spontaneous drug resistance to multiple anti-cancer agents
(Abe et al., 1994a). We examined the sensitivity of these three
human glioma cell lines and another, CCF-STTGI, to var-
ious anti-cancer agents such as vincristine, doxorubicin and
etoposide by colony formation assays. Dose-response curves
of the cell lines to these agents were generated, and from
these the LD90 was calculated. The relative resistance of
T98G and IN500 to the three drugs is presented in Table I.
Both were 5.4- to 6.1-fold more resistant to vincristine, and
9.1- to 12.0-fold more resistant to doxorubicin and etoposide
than IN157. CCF-STTG1 cells were around 10-fold more
resistant to vincristine than IN157 cells, but the sensitivity to
etoposide and doxorubicin was similar (Table I).
Expression ofMDR, MRP, DNA topoisomerase I and II a
genes
Northern blot analysis was performed to determine whether
the altered sensitivity of human glioma cell lines was due to
altered expression of drug resistance-relevant genes such as
MDRJ, DNA topoisomerases I and IIa and MRP. Topoiso-
merase I and IIa were expressed at similar levels in IN157,
IN500 and T98G, but at much lower levels in CCF-STTG1
(Figure 2, Table II). MDR] mRNA was overexpressed only
in CCF-STTGI cells, but MRP mRNA was not (Figure 2,
Table II). Consistent with a report by Cole et al. (1992), the
MRP-specific probe hybridised to a 6.5 kb RNA species
(Figure 2). In comparison with drug-sensitive IN157 cells,
MRP mRNA was overexpressed 8- to 10-fold in IN500 and
T98G cell lines, in good agreement with our previous study
(Abe et al., 1994a). The multidrug-resistant phenotype in
IN500 and T98G appeared to be rather closely correlated
more with overexpression of MRP gene than with that of the
MDRJ gene. Furthermore, vincristine resistance in CCF-
STTGI cells appeared to be mediated through the overex-
pression of the MDR] gene.
Reversal effects by combination with cepharanthine, verapamil
or NIK 250, and drug accumulation
We examined whether cepharanthine, verapamil or NIK250
could reverse drug resistance in the human glioma cell lines
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Table I Drug sensitivity and reversal of multidrug resistance in glioma cells using colony formation
assaya
Combined Dose INJ57 T98G IN500 CCF-STTGI
drugs ('gml-') VCRb ETPb DOX' VCR ETP DOX VCR ETP DOX VCR ETP DOX
None 0 1.0c' 1.0 1.0c 6.1 12.0 9.1 5.4 11.8 10.0 10.5 0.9 2.5
Cepharanthine 1.0d 1.0 0.7 0.6 4.8 9.4 4.6 4.2 4.5 3.4 1.4 0.8 1.2
Verapamil 5.0 0.9 0.8 0.8 1.0 1.6 2.0 1.6 1.5 3.2 1.2 0.9 1.4
NIK250 10.0 0.6 0.6 0.5 1.0 0.9 1.4 1.4 1.4 3.0 0.8 0.5 0.9
aThe sensitivity of glioma cell lines to various anti-cancer agents was examined by means of colony
formation assays. Chemosensitising drugs cause less than 10% cytotoxicity when tested alone. bVCR,
vincristine; ETP, etoposide; DOX, doxorubicin. cRelative resistance to vincristine, etoposide and doxorubucin
is presented when the 90% lethal dose (LD90) for each cell line is divided by that for IN157 cells
(LD90 = 0.24 ± 0.06 ngml-' for vincristine, 14.0 + 1.1 ngml-' for etoposide and 1.3 ± 0.2 ngml-' for
doxorubicin) dThe concentration of cepharanthine was 1.Opgml-l for IN157, IN500 and T98G cells, and
0.41Agml-' for CCF-STTGl cells.
NIK250
iCOOCH2 N
CH3
Table II Summary of expression of drug resistance-related genes in
human glioma cells
Gene expression
Cell line Topo IIcc MDR1 MRP
IN157 High Low Low
IN500 High Low High
T98G High Low High
CCF-STTGI Low High Low
Cepharanthine
N C2.) OCH3
4 MRP
Figure 1 Chemical structures of the 1,4-dihydropyridine com-
pounds, NIK250 and cepharanthine.
IN157, T98G, IN500 and CCF-STTG1. Resistance to vin-
cristine, etoposide and doxorubicin in T98G and IN500 cells
was almost completely reversed when combined with vera-
pamil or NIK250 (Table I). Combination with cepharanthine
partially reversed resistance to these agents in T98G or
IN500 cells, whereas drug resistance to vincristine in CCF-
STTG1 cells was almost completely reversed when combined
with cepharanthine.
The cellular accumulation of vincristine, etoposide and
doxorubicin is often reduced in multidrug-resistant cell lines
(Kohno et al., 1988; Matsuo et al., 1990). The reduced
accumulation of etoposide appears to be involved in the
relatively higher drug resistance of T98G (Abe et al., 1994a).
The cellular accumulation of this drug was assayed after 30
and 60 min (Figure 3). The accumulation of [3H]etoposide in
T98G cells reached steady-state levels within 30 min at 37°C,
and cellular accumulation of [3H]etoposide in T98G was
around 20% or less of that in IN157 (Abe et al., 1994a). The
intracellular level of etoposide in T98G cells in the presence
of cepharanthine was only 1.7-fold higher than that in the
absence of any agent. However, accumulation of [3H]etopo-
side increased 2.6- and 3.4-fold in T98G cells line in the
presence of verapamil and NIK250 respectively. On the other
hand, these reversing agents had no effect on the accumula-
tion of [3H]vincristine in T98G cells (Figure 3).
4 MDR1
4Topo I
4 Topo 11
rRNA
Figure 2 Northern blots of MRP, MDR] and DNA topoiso-
merase I and 1Iax in four glioma cell lines. RNA (15jig) from
each glioma cell lines was hybridised with various cDNA probes.
Ribosomal RNA on the gels is shown after ethidium bromide
staining.Reversal agents of MRP- or MDR1-mediated drug resistance
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Figure 3 Effect of cepharanthine, verapamil and NIK250 on
accumulation of (a) etoposide and (b) vincristine. T98G cells were
seeded, then incubated with various reversal agents. The cell-
associated radioactivity was counted, and radioactivity per mg of
protein was determined. Each value is the average of three dishes.
Bars=s.d. *P<0.01. FI, 30min; 1, 60min.
The effect ofcepharanthine, verapamil and NIK250 on
doxorubicin accumulation determined byfluorescence
microscopy
Doxorubicin accumulation in T98G cells was compared in
the presence and absence of modifiers using fluorescence
microscopy. Figure 4 shows that doxorubicin accumulation
in the nuclei of untreated T98G cells was lower than that in
these cells in the presence of NIK250 when incubated for
40 min with doxorubicin. Doxorubicin in the nuclei of T98G
cells was almost completely removed after a further incuba-
tion for 120 min in the absence of drug (Figure 4a and b),
whereas it remained in the cells when the cells were incubated
with NIK250 (Figure 4c and d). We also observed a similar,
but lesser effect, when doxorubicin was combined with vera-
pamil, whereas cepharanthine had almost no effect on doxo-
rubicin accumulation in nuclei (Figure 4e-h). The greater
inhibition on doxorubicin release from the nuclei might be
due to higher affinity of NIK250 to MRP than that of
verapamil.
Discussion
NIK250 almost completely reversed drug resistance to vin-
cristine and etoposide in etoposide/teniposide-resistant cancer
cells with a concomitant increase in the cellular accumulation
of vincristine or etoposide (Watanabe et al., 1991). This
etoposide/teniposide-resistant cell line (KB/VM-4) derived
from human epidermoid cancer KB cells was found to over-
express the MRP, but not the MDR] gene (K Kohno,
Figure 4 Effect of cepharanthine, verapamil and NIK250 on
doxorubicin accumulation using fluorescence microscopy. T98G
cells were incubated for 40min in the presence of doxorubicin
(1 tg ml-') (a, c, e and g), then in its absence for 120 min (b, d, f
and h). T98G cells were incubated with the absence of reversal
agents (a and b), NIK250 (10iggml-') (c and d), verapamil
(5figml-') (e and f) and cepharanthine (1 gml-') (g and h).
unpublished data). Consistent with these findings, this study
demonstrated that NIK250 modulated drug resistance to
etoposide, vincristine and doxorubicin in glioma cells that
overexpress MRP (Table I). Verapamil had similar effects to
NIK250 in potentiation of those drugs. It remains unknown
why drug resistance to doxorubicin in IN500 cells was not
completely reversed in the presence of NIK250 or verapamil
(Table I). The reversal effect of cepharanthine was only
partial in MRP-expressing cells, but almost complete in
MDRJ-expressing CCF-SSTGl cells. Both NIK250 and vera-
pamil induced drug resistance reversal effects in both MRP-
and P-gp-mediated drug resistance, although cepharanthine
had rather a selective effect upon P-gp-mediated drug resis-
tance. MRP shows 15% homology to the MDRJ gene (Cole
et al., 1992), but NIK250 or verapamil might recognise such
a homologous structure in both ATP-binding membranous
glycoprotein molecules, resulting in a reversal of multidrug
resistance mediated through P-gp and MRP.
NIK250 and verapamil overcame drug resistance to doxo-
rubicin, etoposide and vincristine (Table I). Among the three
anti-cancer agents which are potentiated, intracellular
accumulation of doxorubicin and etoposide was increased in
the presence of these modifiers (Figures 3 and 4), but no
apparent accumulation of vincristine was observed (Figure
3). The reversal of vincristine resistance by NIK250 or
verapamil in T98G and IN500 cells appeared not to be
mediated through enhanced accumulation of this tubulin-
targeting anti-cancer agent. Cole et al. (1994) have demon-
strated that verapamil and cyclosporin A markedly increase
vincristine sensitivity in MRP-transfected cells, but only a
slight increase in vincristine accumulation is observed. They
suggested that the mechanisms by which verapamil andReversalagents ofMRP- orMDRI-mediated drugresistance
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cyclosporin A enhance the drug sensitivity of these cells is
unlikely to be the result of a direct interaction of these agents
with MRP (Cole et al., 1994). Interaction of vincristine with
its cellular target, possibly tubulin, might increase the
cytotoxicity of the chemosensitising agents themselves -
NIK250 and verapamil. However, further studies are requir-
ed to determine whether this effect is closely involved in their
reversal of MRP-mediated vincristine resistance.
Although MRP appears to be closely involved in the
acquisition of multidrug resistance in cancer cells (Barrand et
al., 1994; Grant et al., 1994), the underlying mechanism of
MRP-mediated drug resistance still remains unknown. Cal-
cium antagonists such as verapamil, cyclosporins and other
resistance modifiers which can efficiently reverse P-gp-
mediated multidrug resistance in vitro show a weak chemo-
sensitising effect on non-P-gp-mediated multidrug resistance
(Slovak et al., 1988; Cole et al., 1989; Meijer et al., 1991).
Barrand et al. (1993) have also demonstrated that cyclo-
sporin A and its analogue, PSC-833, as well as verapamil,
induce only a small degree of chemosensitisation to vincris-
tine and doxorubicin in a human large-cell lung cancer cell
line overexpressing MRP. In contrast, Cole et al. (1994) have
reported the dramatic chemosensitisation by verapamil of
cellular sensitivity to vincristine and doxorubicin in cells
transfected with a full-length MRP complementary DNA.
The variability of chemosensitisation in various MRP-
overexpressing cell lines suggests that the mechanisms by
which these reversing agents act may depend upon the cell
types involved, but this remains to be determined. A relevant
study by Rhodes et al. (1994) has demonstrated that inhibi-
tors of H+-ATPase, such as 7-chloro-4-nitrobenz-2-oxa-1,3-
diazole and bufilomycin Al, could modifly non-P-gp-medi-
ated multidrug resistance in human lung cancer cells. It
remains to be determined whether or not dihydropyridine
analogues inhibit H+-ATPase.
In conclusion, this study demonstrated that accumulation
of etoposide and doxorubicin in T98G cells is enhanced by
NIK250 or verapamil, but only slightly, if at all, by
cepharanthine. These data suggest that both NIK250 and
verapamil can modifiy both P-gp- and MRP-mediated drug
resistance, but that cepharanthine modifies only that
mediated by P-gp.
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